Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.38 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.36 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.36 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14990906 | 1.00 | APOBEC3A (0.50) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| SCHEMBL172067 | 0.98 | APOBEC3A (0.52) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Hydrochloric Acid SCHEMBL1202789 | 0.96 | APOBEC3A (0.50) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Hydrochloric Acid SCHEMBL15240369 | 0.96 | APOBEC3A (0.50) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Bromide SCHEMBL3309184 | 0.89 | APOBEC3A (0.56) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| SCHEMBL12101179 | 0.87 | APOBEC3A (0.58) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Bromide SCHEMBL7283805 | 0.86 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Bromide SCHEMBL14990640 | 0.86 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| SCHEMBL3307726 | 0.84 | APOBEC3A (0.59) | APOBEC3AAPOBEC3GDRD2RAD52RECQL | |
| Trifluoroacetic Acid SCHEMBL31143352 | 0.83 | HDAC2 (0.42) | APOBEC3AAPOBEC3GDRD2RAD52RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2014086478-A1 | INHIBITORS OF MALT1 PROTEASE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ADRA2A 4577/4885ADRA2B 4525/4885ADRA2C 4434/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ADRA2A 4577/4885ADRA2B 4525/4885ADRA2C 4434/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ADRA2A 4357/4885ADRA2B 4266/4885ADRA2C 4205/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ADRA2A 4577/4885ADRA2B 4525/4885ADRA2C 4434/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ADRA2A 4577/4885ADRA2B 4525/4885ADRA2C 4434/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ADRA2A 4357/4885ADRA2B 4266/4885ADRA2C 4205/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ADRA2A 4357/4885ADRA2B 4266/4885ADRA2C 4205/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ADRA2A 4357/4885ADRA2B 4266/4885ADRA2C 4205/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ADRA2A 4357/4885ADRA2B 4266/4885ADRA2C 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.